OncoSec Medical Inc

+0.02 (+0.93%)
Products, Regulatory

OncoSec Enters Into Agreement With Merck For Pivotal Global Phase 3 Study, Keynote-C87, Of Tavo Combined With Keytruda

Published: 07/06/2021 20:07 GMT
OncoSec Medical Inc (ONCS) - Oncosec Enters Into a Collaboration Agreement With Merck for a Pivotal Global Phase 3 Study, Keynote-c87, of Tavo™ Combined With Keytruda® for Late-stage Metastatic Melanoma.
Oncosec Medical Inc - Keynote-c87 Intends to Enroll Approximately 400 Patients and is Planned to Be Conducted in U.S., Canada, Eu, and Australia.
Oncosec Medical Inc - Under Terms of Agreement, Merck Will Provide Keytruda , While Oncosec Will Provide Investigational Drug, Tavo.
Oncosec Medical Inc - Each Party Will Be Responsible for Its Own Internal Costs, With Oncosec Covering Third Party Costs.
Oncosec Medical Inc - Keynote-c87 is Intended to Support Accelerated Approval by U.S. FDA And/or Serve As a Pivotal Study to Support a Full Licensure.